Sen. Josh Hawley has introduced legislation to strip FDA approval for mifepristone as medication abortion now makes up the majority of U.S. abortions, shifting the fight from clinics to pills prescribed online and delivered by mail. The proposal forces a clash between Congress and the agency that cleared the drug decades ago, while pro-life lawmakers argue rising use and telemedicine access have exposed regulatory gaps and risks they say the FDA has downplayed.
For years the pro-life movement predicted the battle over abortion would move toward medication, and recent data now shows medication abortion accounts for roughly 63 percent of abortions nationwide. That change has practical consequences for enforcement, public health oversight, and the balance between federal authority and state laws passed after Roe was overturned. Republicans who back Hawley’s bill see this as a necessary confrontation to restore law and order around abortion policy.
Hawley framed the issue as both a safety and a legal problem, arguing the drug has proven risky and prone to misuse. He is pushing Congress to revoke the FDA’s approval in order to realign federal policy with states that have limited or banned abortion after the fall of Roe. The senator’s move rejects the idea that the status quo—where pills can be prescribed via telehealth and mailed across state lines—can remain unchallenged.
“We’ve known for years that mifepristone is risky but it’s really just in the last few years that we’ve learned that this drug is inherently dangerous and it is inherently prone to abuse,” Hawley said while discussing the legislation.
Supporters of the legislation point to research they say shows complications tied to mifepristone may be higher than federal reports indicate. Hawley referenced a study that he summarized as showing severe outcomes in a notable share of cases, noting specifics that alarm his constituents and fellow lawmakers. Those concerns are central to the argument that the FDA has been insufficiently transparent about safety data and adverse events.
“What it means in practice is internal infections, sepsis, a trip to the emergency room, a life-threatening condition, in 11 percent of cases,” he said, referencing research examining hundreds of thousands of prescriptions.
The rise of medication abortion has upended the older regulatory model that focused on clinics, in-person medical supervision, and surgical procedures. Now a woman can begin the process with an online consultation and receive pills by mail, often crossing state lines and sidestepping clinic-based rules. That evolution is why pro-life lawmakers view federal action as the only realistic path to address what they call a nationwide policy problem.
Republicans backing the bill argue the FDA’s original approval, granted more than twenty years ago, didn’t anticipate telemedicine and mass mail-order distribution becoming routine. They contend this technological and logistical shift has created loopholes that allow providers to operate across states with conflicting laws. The result, they say, is a mismatch between federal oversight and state-level protections put in place after Roe.
Critics of the legislation counter that revoking approval would politicize the FDA and limit access to a medical option many consider safe and necessary. Hawley’s team, however, insists the proposal is a law-and-safety measure, not merely a political stunt, and that Congress must reclaim authority when an agency’s decisions clash with newly asserted state rights and emerging risks. That argument is designed to appeal to lawmakers concerned with both federal overreach and public health integrity.
Practically speaking, succeeding in Congress would be difficult given the chamber’s narrow margins and the complex legal landscape surrounding drug approvals. Still, the bill’s introduction matters for the broader debate because it elevates a direct federal response rather than continuing to leave the issue to courts and state legislatures. For Republicans pushing accountability at the agency level, that visibility is part of a longer campaign to reshape how abortion policy is enforced nationwide.
The policy fight is now as much about distribution channels and regulatory control as it is about the moral and legal questions that have long divided the country. Medication abortion’s dominance has forced Republicans to adapt tactics and pursue avenues—like challenging FDA approvals—that were less prominent when clinics were the primary battleground. Hawley’s proposal is a clear example of that strategic shift, aimed at halting a practice that has become harder for states to regulate.
Whether the bill will move beyond introduction is uncertain, but it signals a willingness among pro-life conservatives to press Congress into taking a more active role. As the debate continues, lawmakers will weigh safety claims, legal authority, and political feasibility while voters watch how elected officials respond to an issue that now centers on pills, telemedicine, and federal agency power.
Add comment